Genfit SA (ADR) (OQ:GNFT)
Business Focus: Biotechnology & Medical Research
Dec 17, 2021 07:30 am ET
Thinking about buying stock in Spruce Biosciences, Bottomline Technologies, BioLine RX, Obseva SA, or Genfit SA?
NEW YORK, Dec. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPRB, EPAY, BLRX, OBSV, and GNFT.
Dec 17, 2021 01:00 am ET
Jan 13, 2021 04:15 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Genfit SA (“Genfit” or “the Company”) (NASDAQ:
Dec 23, 2020 03:11 pm ET
Shareholder Alert: Robbins LLP Announces That Genfit SA (GNFT) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Genfit SA American Depository Shares (NASDAQ: GNFT) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Act of 1933 pursuant to the Company’s initial public offering in the U.S., conducted on March 27,
Dec 23, 2020 02:00 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Genfit S.A. (“Genfit” or the “Company”) (NASDAQ:
Dec 23, 2020 12:00 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Genfit S.A. (“Genfit” or the “Company”) (NASDAQ: GNFT) investors concerning the Company’s possible violations of federal securities laws.
Dec 22, 2020 07:38 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Genfit S.A. (“Genfit” or the “Company”) (NASDAQ:
Mar 04, 2020 04:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT
Pomerantz LLP is investigating claims on behalf of investors of Genfit SA (“Genfit” or the “Company”) (NASDAQ: GNFT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Feb 25, 2020 11:00 am ET
GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Genfit SA (“Genfit” or the "Company”) (NASDAQ: GNFT). Investors who purchased Genfit securities are encouraged to obtain...
Feb 24, 2020 02:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT
Pomerantz LLP is investigating claims on behalf of investors of Genfit SA (“Genfit” or the “Company”) (NASDAQ: GNFT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jun 24, 2019 04:31 pm ET
Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region
Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. Under the terms of the agreement, Terns acquires the exclusive right to develop, register, and market elafibranor for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) in Greater China (mainland China, Hong Kong, Macau, and Taiwan). GENFIT will receive a $35 million up
Mar 27, 2019 06:13 pm ET
Nasdaq Welcomes GENFIT S.A. (Nasdaq: GNFT) to The Nasdaq Stock Market
GENFIT S.A. (Nasdaq: GNFT), a late-stage clinical biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, rang the Nasdaq MarketSite...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.